VEMLIDY is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Gilead Sciences, Inc.. The primary component is Tenofovir Alafenamide Fumarate.
Product ID | 61958-2301_071939d1-7479-4b7c-bde2-eff9f1019017 |
NDC | 61958-2301 |
Product Type | Human Prescription Drug |
Proprietary Name | VEMLIDY |
Generic Name | Tenofovir Alafenamide |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2016-11-10 |
Marketing Category | NDA / NDA |
Application Number | NDA208464 |
Labeler Name | Gilead Sciences, Inc. |
Substance Name | TENOFOVIR ALAFENAMIDE FUMARATE |
Active Ingredient Strength | 25 mg/1 |
Pharm Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleosides [CS] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2016-11-10 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA208464 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2016-11-10 |
Ingredient | Strength |
---|---|
TENOFOVIR ALAFENAMIDE FUMARATE | 25 mg/1 |
SPL SET ID: | 72e6b33c-0351-4070-9172-eeaa186c01d2 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
VEMLIDY 86765021 5001852 Live/Registered |
Gilead Sciences Ireland UC 2015-09-22 |